In prostate cancer, p300 acetylation could either prevent AR binding directly by β-catenin, as suggested by Levy et al. [28], or it could alternatively affect FKBP52 binding to β-catenin, thereby favoring the binding of TCF4 over AR. The gene discussed is EP300; the disease is prostate cancer.